90 related articles for article (PubMed ID: 17339240)
21. Involvement of interaction between Fractalkine and CX3CR1 in cytotoxicity of natural killer cells against tumor cells.
Zhang X; Wei H; Wang H; Tian Z
Oncol Rep; 2006 Feb; 15(2):485-8. PubMed ID: 16391873
[TBL] [Abstract][Full Text] [Related]
22. The CX3C chemokine fractalkine (CX3CL1) is detectable in serum of B cell chronic lymphocytic leukemia patients with lymph node involvement.
Morabito F; Merendino RA; Penna G; Cuzzola M; Stelitano C; Callea V; Di Pasquale G; Minciullo PL; Gangemi S
Acta Haematol; 2005; 113(2):152-4. PubMed ID: 15802897
[No Abstract] [Full Text] [Related]
23. Antitumor effect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector.
Gao JQ; Tsuda Y; Katayama K; Nakayama T; Hatanaka Y; Tani Y; Mizuguchi H; Hayakawa T; Yoshie O; Tsutsumi Y; Mayumi T; Nakagawa S
Cancer Res; 2003 Aug; 63(15):4420-5. PubMed ID: 12907614
[TBL] [Abstract][Full Text] [Related]
24. Gene cloning, RNA distribution, and functional expression of mCX3CR1, a mouse chemotactic receptor for the CX3C chemokine fractalkine.
Combadiere C; Gao J; Tiffany HL; Murphy PM
Biochem Biophys Res Commun; 1998 Dec; 253(3):728-32. PubMed ID: 9918795
[TBL] [Abstract][Full Text] [Related]
25. Cloning and characterization of a new type of mouse chemokine.
Rossi DL; Hardiman G; Copeland NG; Gilbert DJ; Jenkins N; Zlotnik A; Bazan JF
Genomics; 1998 Jan; 47(2):163-70. PubMed ID: 9479488
[TBL] [Abstract][Full Text] [Related]
26. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients.
Ohta M; Tanaka F; Yamaguchi H; Sadanaga N; Inoue H; Mori M
Int J Oncol; 2005 Jan; 26(1):41-7. PubMed ID: 15586223
[TBL] [Abstract][Full Text] [Related]
27. Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53.
Shiraishi K; Fukuda S; Mori T; Matsuda K; Yamaguchi T; Tanikawa C; Ogawa M; Nakamura Y; Arakawa H
Cancer Res; 2000 Jul; 60(14):3722-6. PubMed ID: 10919640
[TBL] [Abstract][Full Text] [Related]
28. Single CX3CL1-Ig DNA administration enhances T cell priming in vivo.
Iga M; Boissonnas A; Mahé B; Bonduelle O; Combadière C; Combadière B
Vaccine; 2007 Jun; 25(23):4554-63. PubMed ID: 17493713
[TBL] [Abstract][Full Text] [Related]
29. Expression and targeting of CX3CL1 (fractalkine) in renal tubular epithelial cells.
Durkan AM; Alexander RT; Liu GY; Rui M; Femia G; Robinson LA
J Am Soc Nephrol; 2007 Jan; 18(1):74-83. PubMed ID: 17151328
[TBL] [Abstract][Full Text] [Related]
30. Chemokines promote quiescence and survival of human neural progenitor cells.
Krathwohl MD; Kaiser JL
Stem Cells; 2004; 22(1):109-18. PubMed ID: 14688397
[TBL] [Abstract][Full Text] [Related]
31. The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions.
Schäfer A; Schulz C; Fraccarollo D; Tas P; Leutke M; Eigenthaler M; Seidl S; Heider P; Ertl G; Massberg S; Bauersachs J
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):55-62. PubMed ID: 17082482
[TBL] [Abstract][Full Text] [Related]
32. [A model for colon cancer immunology and immunotherapy: the PRO/REG cell variants].
Martin F; Martin M
Gastroenterol Clin Biol; 2000 Oct; 24(10):923-8. PubMed ID: 11084430
[No Abstract] [Full Text] [Related]
33. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets.
Schulz C; Schäfer A; Stolla M; Kerstan S; Lorenz M; von Brühl ML; Schiemann M; Bauersachs J; Gloe T; Busch DH; Gawaz M; Massberg S
Circulation; 2007 Aug; 116(7):764-73. PubMed ID: 17679613
[TBL] [Abstract][Full Text] [Related]
34. Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis.
Blaschke S; Koziolek M; Schwarz A; Benöhr P; Middel P; Schwarz G; Hummel KM; Müller GA
J Rheumatol; 2003 Sep; 30(9):1918-27. PubMed ID: 12966591
[TBL] [Abstract][Full Text] [Related]
35. Soluble fractalkine in the cerebrospinal fluid of patients with neuropsychiatric lupus.
Sato E; Iikuni N; Yoshio T; Minota S; Kamatani N; Okamoto H
Ann Rheum Dis; 2006 Sep; 65(9):1257-9. PubMed ID: 16905589
[No Abstract] [Full Text] [Related]
36. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype.
Brand S; Hofbauer K; Dambacher J; Schnitzler F; Staudinger T; Pfennig S; Seiderer J; Tillack C; Konrad A; Göke B; Ochsenkühn T; Lohse P
Am J Gastroenterol; 2006 Jan; 101(1):99-106. PubMed ID: 16405540
[TBL] [Abstract][Full Text] [Related]
37. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice.
Inoue A; Hasegawa H; Kohno M; Ito MR; Terada M; Imai T; Yoshie O; Nose M; Fujita S
Arthritis Rheum; 2005 May; 52(5):1522-33. PubMed ID: 15880599
[TBL] [Abstract][Full Text] [Related]
38. Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis--possible role in vascular inflammation.
Bjerkeli V; Damås JK; Fevang B; Holter JC; Aukrust P; Frøland SS
Rheumatology (Oxford); 2007 Sep; 46(9):1422-7. PubMed ID: 17616549
[TBL] [Abstract][Full Text] [Related]
39. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions.
Verge GM; Milligan ED; Maier SF; Watkins LR; Naeve GS; Foster AC
Eur J Neurosci; 2004 Sep; 20(5):1150-60. PubMed ID: 15341587
[TBL] [Abstract][Full Text] [Related]
40. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells.
Ancuta P; Wang J; Gabuzda D
J Leukoc Biol; 2006 Nov; 80(5):1156-64. PubMed ID: 17056766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
